On Monday, Celldex Therapeutics Inc (NASDAQ: CLDX) opened lower -4.64% from the last session, before settling in for the closing price of $22.0. Price fluctuations for CLDX have ranged from $14.40 to $47.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 6.91% annually for the last half of the decade. Company’s average yearly earnings per share was noted -40.83% at the time writing. With a float of $64.51 million, this company’s outstanding shares have now reached $66.38 million.
In an organization with 186 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 78.62%, operating margin of -2873.52%, and the pretax margin is -2366.07%.
Celldex Therapeutics Inc (CLDX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Celldex Therapeutics Inc is 2.84%, while institutional ownership is 109.40%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares.
Celldex Therapeutics Inc (CLDX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -40.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.47% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Check out the current performance indicators for Celldex Therapeutics Inc (CLDX). In the past quarter, the stock posted a quick ratio of 21.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 184.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.70, a number that is poised to hit -0.86 in the next quarter and is forecasted to reach -4.02 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.34 million. That was better than the volume of 0.94 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 72.54%.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 68.33%, which indicates a significant increase from 49.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.26% in the past 14 days, which was lower than the 61.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.32, while its 200-day Moving Average is $23.78. However, in the short run, Celldex Therapeutics Inc’s stock first resistance to watch stands at $21.67. Second resistance stands at $22.37. The third major resistance level sits at $22.81. If the price goes on to break the first support level at $20.53, it is likely to go to the next support level at $20.09. The third support level lies at $19.39 if the price breaches the second support level.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
There are currently 66,384K shares outstanding in the company with a market cap of 1.39 billion. Presently, the company’s annual sales total 7,020 K according to its annual income of -157,860 K. Last quarter, the company’s sales amounted to 700 K and its income totaled -53,800 K.
